
    
      Since T4 (thyroxine) is a potent growth factor in numerous cancer types, the interventional
      approach will be to achieve thyroxine deprivation (hypothyroxinemia).This can be achieved by
      using a dual approach: T3 and methimazole to provide longer term inhibition of thyroid
      hormone synthesis.
    
  